Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195785 | 0.91 | LMNA (0.48) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6843367 | 0.89 | RXRA (0.43) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6843440 | 0.89 | RXRA (0.43) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6838144 | 0.89 | NR4A2 (0.43) | MAPTNR4A2KMT2AMEN1NPC1 | |
| SCHEMBL6843319 | 0.89 | SRD5A2 (0.43) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6845480 | 0.89 | SRD5A2 (0.46) | NR4A2KMT2AMEN1ALDH1A1MMP1 | |
| SCHEMBL6845496 | 0.88 | MAPT (0.42) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6211543 | 0.88 | MRGPRX4 (0.40) | KMT2AMEN1 | |
| SCHEMBL6211990 | 0.88 | PTPN5 (0.47) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL6843437 | 0.87 | CA1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | MAPT 1745/4885NR4A2 2222/4885KMT2A 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.